News Archive

–  ‘We Do Vaccines’ and ‘Know Our Vax’ are new educational efforts that provide information regarding vaccines

–  Programs explain Novavax’ commitment to vaccine development and innovation

GAITHERSBURG, Md., March 10, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the launch of its global unbranded ‘We Do Vaccines’ and ‘Know Our Vax’ programs, educational efforts aimed to help protect the health of people everywhere in the fight against COVID-19 and other deadly infectious diseases, such as influenza.

GAITHERSBURG, Md., March 11, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of stabilized isoamyl nitrite (SIAN), a treatment being developed for known or suspected acute cyanide poisoning. Under an existing multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), and in collaboration with the Southwest Research Institute, Emergent is developing a single-use intranasal spray intended for administration by first responders and medical personnel following a cyanide incident.

“Emergent’s R&D efforts are grounded in our mission – to protect and enhance life,” said Kelly Warfield, Ph.D., senior vice president, research and development at Emergent BioSolutions. “We are committed to advancing unique programs like SIAN, which addresses the need for an easily administered first-line treatment for cyanide poisoning. Intranasal SIAN is being developed for potential use by both civilians and first responders and is part of our portfolio of medical countermeasures focused on priority public health threats identified by the U.S. government.”

In 2003, a group of University of Maryland officials approached then-mayor Martin O’Malley with a development plan for vacant land along West Baltimore Street, adjacent to University of Maryland, Baltimore’s campus. Today, this ambitious project, the University of Maryland BioPark, boasts nearly three dozen life science companies, ranging from leading global firms to mature companies to early-stage ventures. In recent years, the BioPark has attracted a cluster of early-stage medical device companies. For these young companies, the BioPark offers something even more important than a corporate headquarters: a location on UMB’s campus and in the heart of Maryland’s biomed ecosystem.

Image: https://technical.ly/

The Maryland Tech Council has launched two new regional satellite chapters to directly focus on the burgeoning technology sectors in Greater Baltimore and Prince George’s County.

The tech council (MCT) is Maryland’s largest technology and life sciences trade association with more than 450 members. The Baltimore and Prince George’s regional councils are the first sub-chapters launched by the organization.

Image: Marty Rosendale, CEO of the Maryland Tech Council, said the organization created regional chapters “to intentionally unite and empower stakeholders through local advocacy, outreach and growth.” Maryland Tech Council

Human monoclonal antibodies (mAbs) are being used in the clinic to prevent or treat SARS-CoV-2 infection, and experience thus far suggests that combinations of antibodies are potentially able to sustain broad recognition of viral variants as they arise, but developing, testing and approving mAb combination products is complex. One approach to reducing the logistical challenges of combination products is the development of bispecific antibodies (bsAbs) (Fig. 1). In this issue of Nature Immunology, Li et al. report the development and testing of an engineered bispecific human mAb against SARS-CoV-21.

Image: https://www.nature.com

Casimir Further Differentiates Emmes’ Industry-Leading Rare Disease Research Capabilities

ROCKVILLE, Md., March 10, 2022 /PRNewswire/ — Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it has acquired Casimir, a U.S.-based CRO. Casimir has experience in more than 20 rare diseases and has worked with regulators, sponsors and patients to develop outcome measures that capture the nuances of disease progression and treatment benefit.

– Reports Promising Early Data from Lead Clinical Program, JK07, for the Treatment of Heart Failure with Reduced Ejection Fraction –

– Initiates Enrollment in Second Cohort of JK07 Phase 1 Dose Escalation Study –

(Gaithersburg, MD) – March 7, 2022 – Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced it received $32 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd. The investment, which was completed in the fourth quarter of 2021, will be used to advance the current pipeline, including continuation of an ongoing Phase 1b clinical trial and initiation of two additional Phase 1b clinical trials in 2022, and to further expand the pipeline through R&D.

For a small business with a brilliant new idea in the life sciences, a funding infusion can do wonders to help translate that concept into reality. Did you know that the NIH small business programs are the largest source of early-stage capital for the life sciences in the U.S.? These programs set aside over $1.2 billion non-dilutive funds every year — specifically to support small business research and development.